Camena Bioscience Ltd has appointed Gregory P. McGuinness as chief executive officer to support the company’s drive to commercialise a platform for AI-driven antibody discovery, and operational scaling. Mr McGuinness brings 30 years of executive and operational expertise to the field. He was most recently CEO at Inanovate Inc and was also CEO/co-founder of TwiXimo Therapeutics Inc. Other previous senior positions include chief commercial officer at Genturi Inc and VP of business development at DNA Electronics Ltd.
Camena Bioscience announced the appointment on 14 July 2026.
Copyright 2026 Evernow Publishing Ltd.